BioShield Technologies says it has recently received from the U.S. Patent Office an approval extending its AM500 antimicrobial patent, thus securing the rights to a broader array of applications and formularies.
BioShield says approval helps to solidify the company’s positioning in the coatings and other industries to control the growth of bacteria, mold, mildew and algae for either indoor or outdoor applications. The final patent filing and respective claims are anticipated to be issued as a U.S. Registered Patent within the next few months.
“This new patent approval contributes a great deal to our competitive advantage, creates new barriers to entry for our competition to participate in the antimicrobial and antibacterial industries, and further enhances and protects BioShield’s intellectual property portfolio,” Deirdre Baker, BioShield’s general manager, said in a statement. “The approval of this patent further solidifies BioShield’s position in the antimicrobial industry as having one of the broadest product lines that provide the benefit of being essentially non-toxic, water-based, non-leaching and having long-term effectiveness.”
Over the past five years, adds Baker, BioShield has invested over $20 million in product research and development, EPA registrations and patent filings. To date, BioShield has received three U.S. patents and eight EPA registrations, including the first U.S. germ killer and disinfectant against Salmonella cholerasuis, Staphylococcus aureus and other microorganisms.
Based in Norcross, GA, near Atlanta, BioShield is an emerging growth company focused in biotechnology and antimicrobial products.